Literature DB >> 31702939

Cyclic vomiting syndrome: an overview for clinicians.

J Daniel Herlihy1, Sumana Reddy2, Aaron Shanker3, Richard McCallum1.   

Abstract

Introduction: Cyclic vomiting syndrome (CVS) is an under recognized entity causing significant impact on patient's lifestyle. CVS is characterized by recurrent episodes of abdominal pain, nausea, and vomiting leading to many emergency department presentations prior to diagnosis. Patients often have lengthy delays in starting appropriate therapy leading to significant physical and financial hardship. Most cases of cyclic vomiting syndrome are reversible by managing risk factors and starting on appropriate treatment.Areas covered: This review covers the diagnostic criteria, pathophysiology, risk factors, and treatment for CVS and provides a valuable resource for clinicians to review and help with managing this challenging syndrome. The latest literature regarding the diagnosis and management of CVS is summarized.Expert Opinion: The direction for future research in CVS and insights to managing CVS are summarized. The role of pain that can be frequently controlled by tricyclic antidepressants and lorazepam suggests a central nervous system (CNS) origin. A standardized treatment regimen for CVS must be implemented as patients do respond to current therapies but there is often a significant delay in initiation of treatment. Reviewed recent data looking at MRI brain changes in patients with CVS that may lead to a better understanding of the pathophysiology of this disease.

Entities:  

Keywords:  Cyclic vomiting syndrome; abdominal pain; functional GI disorders; nausea; vomiting

Mesh:

Year:  2019        PMID: 31702939     DOI: 10.1080/17474124.2019.1691527

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  1 in total

1.  Death of a young woman with cyclic vomiting: a case report.

Authors:  Ingo von Both; Brittini Santos
Journal:  Forensic Sci Med Pathol       Date:  2021-11-04       Impact factor: 2.007

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.